Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Hyperglycemia 2Lymphoma 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Burkitt Lymphoma 1

Interventions

Cytarabine 89Daunorubicin 45Azacitidine 43Idarubicin 27venetoclax 26fludarabine 26Etoposide 25Cyclophosphamide 25Mitoxantrone 22Decitabine 19Busulfan 19Methotrexate 16Gemtuzumab 14Granulocyte Colony-Stimulating Factor 12Whole-Body Irradiation 10Peripheral Blood Stem Cell Transplantation 10Melphalan 10gilteritinib 9Filgrastim 9fludarabine phosphate 8Tacrolimus 8Mycophenolic Acid 8Cyclosporine 8Tretinoin 7Radiotherapy 7Drug Therapy 7Observation 6Homoharringtonine 6Antilymphocyte Serum 6quizartinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myeloid, Acute × Insulin Glargine × Clear all
NCT00943709 2013-08-30

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

Rutgers, The State University of New Jersey

Phase 3 Withdrawn
LymphoidOther hematologic neoplasm

Congenital Abnormalities, Hyperglycemia, Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡